Cellular Senescence, Aging, and Cancer: Bench to Bedside

Dear Colleagues,

Cellular senescence, which remained an enigma for many years and is mostly an in vitro phenomenon, has now come to the forefront as a leading driver of aging and age-related comorbidities, thanks to the work of several decades of extensive pre-clinical and clinical studies. People have used pharmacological and genetic mouse models to show that targeting senescent cells to treat age- and disease-related conditions such as osteoporosis and metabolic dysfunction is a viable therapeutic strategy. Age has always been a contributing factor to cancer occurrences, and recent work has shown that the inflammatory environment generated by a senescent cell can promote tumorigenesis. Elimination of senescent cells reduces the pro-inflammatory senescence associated secretory phenotype (SASP), and hence the triggers for tumorigenesis. Surveillance and clearance of senescent cells also requires a robust immune system, which is also in play for the treatment of a variety of cancers. The role of immunosenescence in the context of aging and cancer is another aspect which drives several comorbidities. Treatments for cancer, such as chemotherapy and radiotherapy, cause senescence-induced morbidities, but these are also not in isolation and have additional consequences during old age. It is an open question whether delay in age-related comorbidities will also reduce age-related cancer incidences and whether there could be common therapeutics. This Special Issue will collect articles which will address any of these questions.

Dr. Abhishek Chandra
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• cellular senescence
• senolytics
• aging
• cancer
• chemotherapy
• radiotherapy
• healthspan
• lifespan